Latest Safety News

Cynata Therapeutics is on track to deliver key clinical trial results in mid-2026 while maintaining a solid cash runway supported by an imminent R&D tax rebate and equity facility.

WA Kaolin Ltd has reported a record-breaking quarter in sales volume and revenue, driven by operational enhancements and expanding market reach across Asia and domestic sectors.

Avecho Biotechnology advances its pivotal Phase III CBD insomnia trial with 160 patients dosed and secures $2.5 million to accelerate manufacturing and regulatory efforts ahead of a 2026 interim analysis.

Jameson Resources has made significant strides in advancing its Crown Mountain Hard Coking Coal Project, progressing environmental assessments and Indigenous partnerships while securing fresh capital to support development.

Northern Minerals reports a robust Definitive Feasibility Study and secures conditional funding interest, positioning Browns Range as a critical supplier of heavy rare earths by 2028.

Bowen Coking Coal maintained steady production and sales in Q3 2025 while slashing costs by a third through a new mining model, despite ongoing administration and receivership. The company generated positive operating cash flow and advanced key development projects.

Korvest has reported a record $13.2 million profit for FY25, driven by strong performances in its EzyStrut and Galvanising divisions, and is now embarking on a major expansion of its Kilburn manufacturing site.

Vulcan Steel reported a sharp profit decline in FY25 amid tough market conditions but strengthened its balance sheet and expanded into roofing with a major acquisition. Leadership changes set the stage for renewed growth.

KGL Resources has raised A$11 million through a placement led by institutional investors, including Resource Capital Fund, to advance enabling works at its Jervois Copper Project ahead of a Final Investment Decision.

Constellation Technologies reports solid first-quarter progress driven by strong demand for its Callisto Food Safety System and new handheld temperature device, alongside promising integration projects and steady revenue.

Central Petroleum reported a slight dip in sales volumes and revenue for the September quarter, offset by a significant reserves upgrade and a new long-term gas supply agreement that promises cash flow stability.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug candidate NUZ-001 and strengthened its balance sheet with a $5.2 million capital raise. The company is now poised to enter the pivotal HEALEY ALS Platform Trial, marking a significant step forward in its neurodegenerative disease program.